The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
MYC Activation Is a Hallmark of Cancer Initiation and Maintenance
Open accessAbstract
The MYC proto-oncogene has been implicated in the pathogenesis of most types of human tumors. MYC activation alone in many normal cells is restrained from causing tumorigenesis through multiple genetic and epigenetically controlled checkpoint mechanisms, including proliferative arrest, apoptosis, and cellular senescence. When pathologically activated in a permissive epigenetic and/or genetic context, MYC bypasses these mechanisms, enforcing many of the "hallmark" features of cancer, including relentless tumor growth associated with DNA replication and transcription, cellular proliferation and growth, protein synthesis, and altered cellular metabolism. MYC mandates tumor cell fate, by inducing stemness and blocking cellular senescence and differentiation. Additionally, MYC orchestrates changes in the tumor microenvironment, including the activation of angiogenesis and suppression of the host immune response. Provocatively, brief or even partial suppression of MYC back to its physiological levels of activation can result in the restoration of intrinsic checkpoint mechanisms, resulting in acute and sustained tumor regression, associated with tumor cells undergoing proliferative arrest, differentiation, senescence, and apoptosis, as well as remodeling of the tumor microenvironment, recruitment of an immune response, and shutdown of angiogenesis. Hence, tumors appear to be "addicted" to MYC because of both tumor cell-intrinsic, cell-autonomous and host-dependent, immune cell-dependent mechanisms. Both the trajectory and persistence of many human cancers require sustained MYC activation. Multiscale mathematical modeling may be useful to predict when tumors will be addicted to MYC. MYC is a hallmark molecular feature of both the initiation and maintenance of tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells
Nie, Z., Hu, G., Wei, G., Cui, K., Yamane, A., Resch, W., Wang, R., Green, D. R., Tessarollo, L., Casellas, R., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.033 · Cited by 1,075
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Self-citationMYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities
Dang, C. V., Le, A., & Gao, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0889 · Cited by 946
Does the ribosome translate cancer?
Ruggero, D., & Pandolfi, P. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1015 · Cited by 928
Eilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Self-citationc-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874
Self-citationModelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Antisense oligonucleotides: basic concepts and mechanisms.
Dias, N., & Stein, C. A. (2002) · PubMed · Cited by 759
Non-transcriptional control of DNA replication by c-Myc
Dominguez-Sola, D., Ying, C. Y., Grandori, C., Ruggiero, L., Chen, B., Li, M., Galloway, D. A., Gu, W., Gautier, J., & Dalla-Favera, R. (2007) · Nature · doi:10.1038/nature05953 · Cited by 651
Drosophila myc Regulates Cellular Growth during Development
Johnston, L. A., Prober, D. A., Edgar, B. A., Eisenman, R. N., & Gallant, P. (1999) · Cell · doi:10.1016/s0092-8674(00)81512-3 · Cited by 648
Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., Bishop, J. M., & Felsher, D. W. (2002) · Science · doi:10.1126/science.1071489 · Cited by 644
Self-citationPelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 626
Control of c-myc Regulation in Normal and Neoplastic Cells
(1991) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60476-5 · Cited by 618
MYC, Metabolism, Cell Growth, and Tumorigenesis
Dang, C. V. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014217 · Cited by 602
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582
Cancer revoked: oncogenes as therapeutic targets
Felsher, D. W. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1070 · Cited by 556
Self-citationThe Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Soucek, L., Lawlor, E. R., Soto, D., Shchors, K., Swigart, L. B., & Evan, G. I. (2007) · Nature Medicine · doi:10.1038/nm1649 · Cited by 507
Hoffman, B., & Liebermann, D. A. (2008) · Oncogene · doi:10.1038/onc.2008.312 · Cited by 488
Translocations involving c-myc and c-myc function
Boxer, L. M., & Dang, C. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204595 · Cited by 479
Myc pathways provoking cell suicide and cancer
Nilsson, J. A., & Cleveland, J. L. (2003) · Oncogene · doi:10.1038/sj.onc.1207261 · Cited by 462
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
Distinct Thresholds Govern Myc's Biological Output In Vivo
Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L., Johnson, L., & Evan, G. I. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.018 · Cited by 456
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Kessler, J. D., Kahle, K. T., Sun, T., Meerbrey, K. L., Schlabach, M. R., Schmitt, E. M., Skinner, S. O., Xu, Q., Li, M. Z., Hartman, Z. C., et al. (2012) · Science · doi:10.1126/science.1212728 · Cited by 433
Transient excess of MYC activity can elicit genomic instability and tumorigenesis
Felsher, D. W., & Bishop, J. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3940 · Cited by 419
Self-citationD'Cruz, C. M., Gunther, E. J., Boxer, R. B., Hartman, J. L., Sintasath, L., Moody, S. E., Cox, J. D., Ha, S. I., Belka, G. K., Golant, A., et al. (2001) · Nature Medicine · doi:10.1038/84691 · Cited by 418
Reversibility of acute B-cell leukaemia induced by BCR–ABL1
Huettner, C. S., Zhang, P., Van Etten, R. A., & Tenen, D. G. (2000) · Nature Genetics · doi:10.1038/71691 · Cited by 413
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.
Escot, C., Theillet, C., Lidereau, R., Spyratos, F., Champeme, M. H., Gest, J., & Callahan, R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4834 · Cited by 412
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408 · cited 1×
“Later, MYC was illustrated to be activated through chromosomal translocation in Burkitt lymphoma (see Conacci-Sorrell et al. 2014).”
BackgroundChakravarty, D., Santos, E., Ryder, M., Knauf, J. A., Liao, X.-H., West, B. L., Bollag, G., Kolesnick, R., Thin, T. H., Rosen, N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46382 · Cited by 391
Function of the c-Myc Oncogenic Transcription Factor
Dang, C. V., Resar, L. M. S., Emison, E., Kim, S., Li, Q., Prescott, J. E., Wonsey, D., & Zeller, K. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4686 · Cited by 379
High-throughput retroviral tagging to identify components of specific signaling pathways in cancer
Mikkers, H., Allen, J., Knipscheer, P., Romeyn, L., Hart, A., Vink, E., & Berns, A. (2002) · Nature Genetics · doi:10.1038/ng950 · Cited by 377
Verdine, G. L., & Walensky, L. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2184 · Cited by 361
Makino, R., Hayashi, K., & Sugimura, T. (1984) · Nature · doi:10.1038/310697a0 · Cited by 359
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339
Self-citationMurray, M. J., Cunningham, J. M., Parada, L. F., Dautry, F., Lebowitz, P., & Weinberg, R. A. (1983) · Cell · doi:10.1016/0092-8674(83)90017-x · Cited by 337
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301
Neto-Silva, R. M., de Beco, S., & Johnston, L. A. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.09.009 · Cited by 287
Functional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima, M., Howie, H. L., Imakura, M., Walsh, R. M., Annis, J. E., Chang, A. N., Frazier, J., Chau, B. N., Loboda, A., Linsley, P. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121119109 · Cited by 242
Li, D., Shimamura, T., Ji, H., Chen, L., Haringsma, H. J., McNamara, K., Liang, M.-C., Perera, S. A., Zaghlul, S., Borgman, C. L., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.005 · Cited by 238
A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenes
Sharma, S. V., Gajowniczek, P., Way, I. P., Lee, D. Y., Jiang, J., Yuza, Y., Classon, M., Haber, D. A., & Settleman, J. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.014 · Cited by 233
Antisense therapy in oncology: new hope for an old idea?
Tamm, I., Dörken, B., & Hartmann, G. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05629-x · Cited by 229
Therapeutic Strategies to Inhibit MYC
McKeown, M. R., & Bradner, J. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014266 · Cited by 222
Retroviral insertional mutagenesis as a strategy to identify cancer genes
Jonkers, J., & Berns, A. (1996) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(95)00020-g · Cited by 194
Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J. R., Tabor, V., Aichele, P., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.043 · Cited by 184
Werner syndrome protein limits MYC-induced cellular senescence
Grandori, C., Wu, K.-J., Fernandez, P., Ngouenet, C., Grim, J., Clurman, B. E., Moser, M. J., Oshima, J., Russell, D. W., Swisshelm, K., et al. (2003) · Genes & Development · doi:10.1101/gad.1100303 · Cited by 180
C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression
Gamberi, G., Benassi, M. S., Bohling, T., Ragazzini, P., Molendini, L., Sollazzo, M. R., Pompetti, F., Merli, M., Magagnoli, G., Balladelli, A., et al. (1998) · Oncology · doi:10.1159/000011912 · Cited by 179
Endogenous Myc maintains the tumor microenvironment
Sodir, N. M., Swigart, L. B., Karnezis, A. N., Hanahan, D., Evan, G. I., & Soucek, L. (2011) · Genes & Development · doi:10.1101/gad.2038411 · Cited by 179
Boxer, R. B., Jang, J. W., Sintasath, L., & Chodosh, L. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.013 · Cited by 178
Cao, Z., Fan-Minogue, H., Bellovin, D. I., Yevtodiyenko, A., Arzeno, J., Yang, Q., Gambhir, S. S., & Felsher, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3367 · Cited by 178
Self-citationYang, D., Liu, H., Goga, A., Kim, S., Yuneva, M., & Bishop, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008366107 · Cited by 177
MYC and Mitochondrial Biogenesis
Morrish, F., & Hockenbery, D. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014225 · Cited by 177
Ji, H., Wang, Z., Perera, S. A., Li, D., Liang, M.-C., Zaghlul, S., McNamara, K., Chen, L., Albert, M., Sun, Y., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4592 · Cited by 174
Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29.
Alitalo, K., Bishop, J. M., Smith, D. H., Chen, E. Y., Colby, W. W., & Levinson, A. D. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.1.100 · Cited by 173
Cdc45 Is a Critical Effector of Myc-Dependent DNA Replication Stress
Srinivasan, S. V., Dominguez-Sola, D., Wang, L. C., Hyrien, O., & Gautier, J. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.002 · Cited by 164
Sheiness, D. K., Fanshier, L., & Bishop, J. M. (1978) · Journal of Virology · doi:10.1128/jvi.28.2.600-610.1978 · Cited by 161
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression
Karlsson, A. E., Deb-Basu, D., Cherry, A. M., Turner, S., Ford, J. M., & Felsher, D. W. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732638100 · Cited by 154
Self-citationGiuriato, S., Ryeom, S. W., Fan, A. C., Bachireddy, P., Lynch, R. C., Rioth, M. J., van Riggelen, J., Kopelman, A. M., Passegue, E. A., Tang, F. L. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608017103 · Cited by 152
Self-citationRetroviral insertional mutagenesis:Tagging cancer pathways
Mikkers, H. M. M., & Berns, A. J. M. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)88304-5 · Cited by 147
Developmental Context Determines Latency of MYC-Induced Tumorigenesis
Beer, S., Zetterberg, A., Ihrie, R. A., McTaggart, R., Yang, Q., Bradon, N., Arvanitis, C., Attardi, L. D., Feng, S., Ruebner, B. H., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020332 · Cited by 145
Self-citationKawate, S., Toshio, F., Ohwada, S., Watanuki, A., & Morishita, Y. (1999) · Oncology · doi:10.1159/000012024 · Cited by 142
Overexpression of MYC causes p53 -dependent G 2 arrest of normal fibroblasts
Felsher, D. W., Zetterberg, A., Zhu, J., Tlsty, T. D., & Bishop, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190327097 · Cited by 138
Self-citationSavino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M. D., Evan, G. I., Soucek, L., & Nasi, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022284 · Cited by 136
The MYC Oncogene as a Cancer Drug Target
Hermeking, H. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481949 · Cited by 133
Drugging the undruggable: Transcription therapy for cancer
Yan, C., & Higgins, P. J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.002 · Cited by 130
c-MYC-Induced Genomic InstabilityPreprint
Kuzyk, R., & Mai, S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014373 · Cited by 128
High-throughput insertional mutagenesis screens in mice to identify oncogenic networks
Kool, J., & Berns, A. J. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2647 · Cited by 128
MYC and Transcription ElongationPreprint
Rahl, P. B., & Young, R. A. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a020990 · Cited by 120
Karlsson, A. E., Giuriato, S., Tang, F. L. M., Weier, J. F., Levan, G., & Felsher, D. W. (2003) · Blood · doi:10.1182/blood-2002-10-3091 · Cited by 117
Self-citationvan Riggelen, J., Müller, J., Otto, T., Beuger, V., Yetil, A., Choi, P. S., Kosan, C., Möröy, T., Felsher, D. W., & Eilers, M. (2010) · Genes & Development · doi:10.1101/gad.585710 · Cited by 114
Self-citationChromosomal regions involved in the pathogenesis of osteosarcomas
Stock, C., Kager, L., Fink, F., Gadner, H., & Ambros, P. F. (2000) · Genes Chromosomes and Cancer · Cited by 113
Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy
Shachaf, C. M., & Felsher, D. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1172 · Cited by 103
Self-citationMYC Can Induce DNA Breaks In vivo and In vitro Independent of Reactive Oxygen Species
Ray, S., Atkuri, K. R., Deb-Basu, D., Adler, A. S., Chang, H. Y., Herzenberg, L. A., & Felsher, D. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3115 · Cited by 98
Self-citationBcl-2 Mediates Chemoresistance in Matched Pairs of Primary Eμ-myc Lymphomas in Vivo
Schmitt, C. A., & Lowe, S. W. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0372 · Cited by 97
Wu, C.-H., Sahoo, D., Arvanitis, C., Bradon, N., Dill, D. L., & Felsher, D. W. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000090 · Cited by 96
Self-citationOncogene Addiction versus Oncogene Amnesia: Perhaps More than Just a Bad Habit?
Felsher, D. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5832 · Cited by 94
Self-citationGenomic and Proteomic Analysis Reveals a Threshold Level of MYC Required for Tumor Maintenance
Shachaf, C. M., Gentles, A. J., Elchuri, S. V., Sahoo, D., Soen, Y., Sharpe, O., Perez, O. D., Chang, M., Mitchel, D., Robinson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6192 · Cited by 93
Self-citationMYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
Clegg, N. J., Couto, S. S., Wongvipat, J., Hieronymus, H., Carver, B. S., Taylor, B. S., Ellwood‐Yen, K., Gerald, W. L., Sander, C., & Sawyers, C. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017449 · Cited by 92
MET and MYC cooperate in mammary tumorigenesis
Welm, A. L., Kim, S., Welm, B. E., & Bishop, J. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500470102 · Cited by 91
MYC and the Control of DNA ReplicationPreprint
Dominguez-Sola, D., & Gautier, J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014423 · Cited by 91
c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines.
Mai, S., Hanley-Hyde, J., & Fluri, M. (1996) · PubMed · Cited by 85
Reversible lymphomagenesis in conditionally c‐MYC expressing mice
Marinković, D., Marinković, T., Mahr, B., Heß, J., & Wirth, T. C. (2004) · International Journal of Cancer · doi:10.1002/ijc.20099 · Cited by 82
Molecular Mechanisms of Hepatocarcinogenesis in Transgenic Mouse Models of Liver Cancer
Calvisi, D. F., & Thorgeirsson, S. S. (2005) · Toxicologic Pathology · doi:10.1080/01926230590522095 · Cited by 77
Lawlor, E. R., Soucek, L., Swigart, L. B., Shchors, K., Bialucha, C. U., & Evan, G. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3826 · Cited by 74
Synthetic Lethal Screens as a Means to Understand and Treat MYC-Driven CancersPreprint
Cermelli, S., Jang, I. S., Bernard, B. M., & Grandori, C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014209 · Cited by 71
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S. V., Goldstein, M. J., Shirer, A. E., Sharpe, O., Chen, J., Mitchell, D. J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-048033 · Cited by 63
Self-citationCellular MYCro Economics: Balancing MYC Function with MYC ExpressionPreprint
Levens, D. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014233 · Cited by 60
Giuriato, S., Rabin, K. R., Fan, A. C., Shachaf, C. M., & Felsher, D. W. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.11.002 · Cited by 58
Self-citationA Myc-Induced Apoptosis Pathway Surfaces
Green, D. R. (1997) · Science · doi:10.1126/science.278.5341.1246 · Cited by 52
Cellular MYCro Economics: Balancing MYC Function with MYC ExpressionPreprint
Levens, D. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a022483 · Cited by 47
O'Shea, J. M., & Ayer, D. E. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014258 · Cited by 47
Hepatotoxin-Induced Changes in the Adult Murine Liver Promote MYC-Induced Tumorigenesis
Beer, S., Komatsubara, K. M., Bellovin, D. I., Kurobe, M., Sylvester, K. G., & Felsher, D. W. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002493 · Cited by 46
Self-citationCompere, S. J., Baldacci, P., Sharpe, A. H., Thompson, T. C., Land, H., & Jaenisch, R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2224 · Cited by 45
Conditionally MYC:insights from novel transgenic models
Arvanitis, C., & Felsher, D. W. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.043 · Cited by 44
Self-citationSurvival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation
Tran, P. T., Bendapudi, P. K., Lin, H. J., Choi, P. S., Koh, S., Chen, J., Horng, G., Hughes, N. P., Schwartz, L. H., Miller, V. A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002018 · Cited by 44
Self-citationAntisense Strategies for Oncogene Inactivation
Stein, C., Benimetskaya, L., & Mani, S. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.003 · Cited by 44
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction
Choi, P. S., van Riggelen, J., Gentles, A. J., Bachireddy, P., Rakhra, K., Adam, S. J., Plevritis, S. K., & Felsher, D. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107303108 · Cited by 43
Self-citationApoptosis Induced by c-Myc Overexpression Is Dependent on Growth Conditions
Gibson, A. W., Cheng, T., & Johnston, R. N. (1995) · Experimental Cell Research · doi:10.1006/excr.1995.1166 · Cited by 40
Retroviral insertional mutagenesis: Tagging cancer pathways
MIKKERS, H., & Berns, A. J. M. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)88255-6 · Cited by 40
Cavin, L. G., Wang, F., Factor, V. M., Kaur, S., Manickam, V., Thorgeirsson, S. S., & Arsura, M. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0186 · Cited by 32
Bachireddy, P., Rakhra, K., & Felsher, D. W. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04514.x · Cited by 28
Self-citationTumor Dormancy: Death and Resurrection of Cancer As Seen through Transgenic Mouse Models
Felsher, D. W. (2006) · Cell Cycle · doi:10.4161/cc.5.16.3111 · Cited by 26
Self-citationDeocampo, N. D., Wilson, M. R., & Trosko, J. E. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.501 · Cited by 22
Can Antitumor Immunity Help to Explain “Oncogene Addiction”?
Restifo, N. P. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.002 · Cited by 19
Cerni, C., Mougneau, E., Zerlin, M., Julius, M., Marcu, K. B., & Cuzin, F. (1986) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71562-4_28 · Cited by 17
Pastorino, F., Brignole, C., Marimpietri, D., et al. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1322.010 · Cited by 13
Mendrysa, S. M., Akagi, K., Roayaei, J., Lien, W., Copeland, N. G., Jenkins, N. A., & Eisenman, R. N. (2010) · Genes & Cancer · doi:10.1177/1947601910374875 · Cited by 12
Cited by
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Self-citationA Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis
Mussbacher, M., Salzmann, M., Brostjan, C., Hoesel, B., Schoergenhofer, C., Datler, H., Hohensinner, P., Basílio, J., Petzelbauer, P., Assinger, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00085 · Cited by 596
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
Metadata
- Authors
- Gabay, M., Li, Y., & Felsher, D. W.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-06-01
- Volume
- 4
- Issue
- 6
- Pages
- a014241-a014241
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2162723598
- Cited by
- 818
- References
- 125
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.